Oncology

Overview

Invicro uniquely combines operational excellence with extensive scientific and medical expertise. Our goal is to drive the advancement of translational cancer research, aid in cancer drug development and develop imaging methods and tools that enable precision medicine. We have experience working with a wide range of therapeutics, including small molecules, peptides, antibodies, multi-specific proteins, CAR-T cells, and many more. Preclinically and clinically, Invicro offers a wide variety of oncology biomarker solutions, including:

Central imaging core lab for Phase 0-IV clinical studies
Preclinical/Clinical novel molecular imaging tracers
In vitro, in vivo, and ex vivo techniques in rodents through NHPs
Autoradiography, histology and quantitative immunohistochemistry
Qualitative and quantitative image analytics

Capabilities

Radiochemistry

Invicros radiochemistry team has experience with almost all commercially available radioisotopes used for PET/SPECT imaging and several used in targeted radiotherapy. Our capabilities span from first-in-human clinical studies to GMP implementation of novel radiotracers, including:

Learn More

Rodent Models

We have experience with multiple rodent models and the flexibility to either produce models in-house or receive them from outside vendors or collaborators. Common models include:

Syngeneic models
Human xenograft tumors in immunocompromised mice
Humanized mouse models
GEMM mouse model

We also work with larger species including canine, porcine, and non-human primates (NHP).

Clinical Core Lab

Invicro has a central imaging core lab, including study design, site set-up and training, development of imaging protocol, expert blinded reads and full 21 CFR Part 11 compliance. We have qualitative and advanced quantitative analysis techniques, including:

Segmentation
Image co-registration
Radiation dosimetry
Mechanistic pharmacokinetic modeling including PBPK modeling
Tracer kinetic modeling
Radiomics
Imaged-based machine learning
Full service independent blind reads or collect and hold capabilities
Response criteria – RANO, Lugano, PCWG, IMWG, RECIST, Cheson, iRECIST, irRECIST, irRC and LYRIC

Invicro also brings experience in PET bio-distribution studies using radiolabeled anti-cancer agents.

Focal adhesion kinase inhibitor GSK2256098 (Neuro Oncol. 2018 May 17)
Lapatinib (EJNMMI Res. 2015 Apr 30;5:30)

Learn More

Quantitative Oncology Analytics

The medical image analysis team supports standard analysis of FDG PET imaging, including PERCIST and other SUV-based metrics, metabolic tumor volume and total lesion glycolysis. The image analysis team also specializes in developing and applying a broad range of tools to support advanced quantitative oncology tracer characterization and analytics across a broad range of modalities and studies. Some examples include:

Powerful, multi-modal tumor and organ Segmentation tools
A range of flexible Biomathematical Modeling tools
Dosimetry calculations across radionuclide, administration route, and species
Integrated Radiomics pipelines using standard and custom feature vectors
Preclinical and clinical support for Tracer Characterization
Sophisticated batch Image Triage and preprocessing methods